8-K: Arrowhead Pharmaceuticals Announces CFO Transition: Ken Myszkowski to Retire, Daniel Apel Appointed as Successor

Arrowhead Pharmaceuticals announces the retirement of CFO Ken Myszkowski and the appointment of Daniel Apel as the new CFO, effective May 13, 2025.

Summary

• Arrowhead Pharmaceuticals announced that Ken Myszkowski will retire as Chief Financial Officer, effective May 13, 2025.
• Mr. Myszkowski has served as CFO since 2009 and will transition to an advisory role until January 31, 2026, with a base salary of $200,000 during this period.
• Daniel Apel has been appointed as the new Chief Financial Officer, effective May 13, 2025.
• Mr. Apel joins from Walgreens Boots Alliance, where he was Global Head of Financial Planning and Analysis.
• He previously held CFO positions at Bayer U.S. and Bayer Canada.
• Mr. Apel will receive an annual base salary of $575,000, a target bonus of 45% of his base salary, and 100,000 restricted stock units vesting over four years.
• The company may also provide $200,000 in relocation benefits to Mr. Apel.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting a smooth CFO transition and the company's financial strength. The appointment of an experienced executive like Daniel Apel is also viewed favorably.

Positives

• Arrowhead is ensuring a smooth transition by retaining Ken Myszkowski as an advisor.
• Daniel Apel brings extensive financial experience from Walgreens Boots Alliance and Bayer.
• Arrowhead's CEO highlights the company's financial strength at the time of Myszkowski's retirement.
• The company is preparing for the commercial launch of plozasiran, pending regulatory approval.

Risks

• The transition of CFOs could present short-term operational challenges.
• The success of the new CFO will depend on his ability to navigate Arrowhead's transition to a commercial-stage company.
• The forward-looking statements in the release are subject to numerous risks and uncertainties, including regulatory approvals and clinical trial outcomes.

Future Outlook

Arrowhead is preparing for the commercial launch of plozasiran, pending regulatory review and approval, and expects Daniel Apel to play a key role in this transition.

Management Comments

• Christopher Anzalone, Ph.D., President and CEO, thanked Ken Myszkowski for his contributions and expressed excitement about Daniel Apel joining Arrowhead.
• Anzalone stated that Myszkowski retires at a time of great financial strength for the company.
• Anzalone believes Apel can make an immediate and important impact on the business as they transition from development to commercial stage.

Industry Context

The appointment of a new CFO is a significant event for a biotechnology company like Arrowhead, especially as it transitions towards commercialization. Daniel Apel's experience in the pharmaceutical industry, including his roles at Bayer and Walgreens Boots Alliance, positions him to contribute to Arrowhead's strategic and financial goals.

Comparison to Industry Standards

• Daniel Apel's compensation package, including a $575,000 base salary and a 45% target bonus, is competitive with CFO compensation at similar-sized pharmaceutical companies.
• For example, CFOs at comparable companies like Alnylam Pharmaceuticals or Ionis Pharmaceuticals typically have base salaries in the range of $500,000 to $700,000, with similar bonus structures.
• The grant of 100,000 restricted stock units is also a common practice to align the CFO's interests with those of the shareholders.

Management Changes

Stakeholder Impact

• Shareholders may view the CFO transition positively, given the experience of the incoming CFO and the company's financial stability.
• Employees will experience a change in leadership within the finance department.
• Customers and partners are unlikely to be directly impacted by this change.

Next Steps

• Daniel Apel will assume the role of CFO on May 13, 2025.
• Ken Myszkowski will transition to an advisory role to assist with the transition until January 31, 2026.
• Arrowhead will continue to pursue regulatory approval for plozasiran and prepare for its commercial launch.

Key Dates

Keywords

Chief Financial Officer, CFO, Daniel Apel, Ken Myszkowski, Arrowhead Pharmaceuticals, Appointment, Retirement, Financial Planning, RNAi Therapeutics